title: ART-123 Asahi Kasei.
abstract: Asahi Kasei is developing a recombinant thrombomodulin (ART-123), a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism [169907]. By September 2000, it had entered phase III trials [383525]. A patent, US-05916874, claiming a method for treating liver injury and whose composition comprises a thrombomodulin, was published in 1999 by the company.
authors.affiliation: Department of Radiology, University of Tübingen, Germany. sascha.khorchidi@uni-tuebingen.de
authors.forename: Sascha
authors.initials: S
authors.lastname: Khorchidi
authors.forename: Ruediger
authors.initials: R
authors.lastname: Bantleon
authors.forename: Rainer
authors.initials: R
authors.lastname: Kehlbach
authors.forename: Gunnar
authors.initials: G
authors.lastname: Tepe
authors.forename: Jakub
authors.initials: J
authors.lastname: Wiskirchen
authors.forename: Stephan H
authors.initials: SH
authors.lastname: Duda
mesh_terms: D000818:Animals; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D013923:Thromboembolism / Q000188:drug therapy*; D018180:Thrombomodulin / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: C472045:ART123; D011994:Recombinant Proteins; D018180:Thrombomodulin